Map Unavailable

Mon, Dec 14, 2020
3:00 pm - 4:00 pm


Our CANRAD Network and CAN-RECOVR winter webinar will take place Monday, December 14, 2020 (3-4 pm EST) featuring a presentation by Dr. Lihi Eder:

 

Do patients with Immune Mediated Inflammatory Diseases have worse COVID-19 related outcomes?

This on-going work, that analyzes administrative health data from Ontario, evaluates several COVID-19 related outcomes, including testing, positivity rate and hospitalizations, in a wide range of IMID populations. The study aims to compare the risk of developing these COVID-19 related outcomes in IMID patients and the general population.

 

Dr. Lihi Eder is a Clinician-Scientist and staff rheumatologist at the Women’s College Research Institute and Assistant Professor of Medicine, University of Toronto, Canada. Dr. Eder has a broad background in rheumatology with specific training and expertise in clinical and genetic epidemiology of psoriatic arthritis and cardiovascular diseases in rheumatic patients. She is Director of the Psoriatic Arthritis program at Women’s College Hospital and co-Director, University of Toronto, Cardio-Rheumatology Program, an interdisciplinary program that aims to improve the management of cardiovascular morbidities in rheumatic patients by developing novel models of care and through research and educational activities.

 

Date: Monday, December 14, 2020

Time: 3:00 pm to 4:00 pm EST

 

Please click the Doodle link to confirm your attendance: https://doodle.com/poll/b3dx5cghsmyxykkg?utm_source=poll&utm_medium=link

 

A Calendar invitation with the Zoom details will be sent to Doodle respondents.

 

Contact Autumn Neville with any questions/comments: autumn.neville@rimuhc.ca

 

A short description of the CAN-RECOVR group:

The CAnadian Network for REsearch on COVID-19 in Rheumatology (CAN-RECOVR) was established to improve the health of Canadians living with rheumatic disease. Our mission is to enhance Canadian collaborative efforts on COVID-19 in rheumatic diseases. We believe that patients with rheumatic diseases represent a key vulnerable population who, if studied, will help us unlock some of the mysteries around COVID-19. This motivates the overarching aim of our collaborative efforts, which is to better understand COVID-19 in rheumatic diseases.  Our objectives are: To support Canadian cohort studies and other Canadian research initiatives related to COVID-19 and rheumatic disease; define priority research questions related to COVID-19 and rheumatic disease; harmonize multi-centre, multi-research network data collection on COVID-19 risk factors and outcomes across existing Canadian rheumatic disease cohorts; conduct a workshop on COVID-19 and rheumatic disease as a forum for presentation and discussion on COVID-19 and rheumatic disease and foster collaboration and interdisciplinary research.  Our current projects are: hydroxychloroquine (HCQ) shortages during COVID-19; antimalarial drugs in arthritis patients exposed to COVID-19, and how COVID-19 affects systemic lupus erythematosus (SLE) patients.


Add a New Event